key: cord-0870299-gme51i7f authors: Hernández-Galdamez, Diego Rolando; González-Block, Miguel Ángel; Romo-Dueñas, Daniela Karola; Lima-Morales, René; Hernández-Vicente, Irma Alejandra; Lumbreras-Guzmán, Marivel; Méndez-Hernández, Pablo title: Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors date: 2020-07-22 journal: Arch Med Res DOI: 10.1016/j.arcmed.2020.07.003 sha: d9211e0b95a7755d2e4be1a890a5fc626bb9c0af doc_id: 870299 cord_uid: gme51i7f Abstract Background The population in Mexico has high prevalence rates of noncommunicable diseases (NCDs). Hospitalization and death of COVID-19 patients in the countries most affected by the pandemic has been associated to chronic comorbidities. Objective To describe the prevalence of NCDs in patients with COVID-19 in Mexico and analyze the increased risk due to comorbidities and risk factors on hospitalization, utilization of intensive care units and death. Methods A cross-sectional study was performed from 212,802 confirmed COVID-19 cases reported by the Ministry of Health up to June 27, 2020. Odds ratios were performed using logistic regression model. Results Up to 47.40% of patients with COVID-19 diagnosis were also reported with a comorbidity, with hypertension being the most frequent (20.12%). The report of at least one NCD significantly increased the risk of death with respect to patients without such diagnoses. Chronic kidney disease increased the risk of death the most (OR 2.31), followed by diabetes (OR 1.69), immunosuppression (OR 1.62), obesity (OR 1.42), hypertension (OR 1.24), chronic obstructive pulmonary disease (OR 1.20). The comorbidities that most increased the risk of ICU and of intubation were diabetes, immunosuppression and obesity. Conclusion NCD comorbidities increase the severity of COVID-19 infection. Given high NCD prevalence rates among the Mexican population, the pandemic poses a special threat to the health system and to society. Special prevention measures need to be strengthened for persons with NCD diagnoses in the short-term. In the mid-term, disease control strategies need to be improved to protect these patients against COVID-19 severity. . On January 30, 2020 the World Health Organization (WHO) declared the COVID-19 outbreak as a public health emergency of international concern and on March 11 issued the declaration of a pandemic (2) . By February 28, 2020 the first three cases of COVID-19 were reported in Mexico, while a total of 85,403 confirmed cases had been reported worldwide. Based on information from the pandemic in China and European countries, the WHO alerted that preexisting non-communicable diseases (NCD) and modifiable risk factors such as smoking and obesity increase the vulnerability of patients with COVID-19 to becoming severely ill, increasing the risk of hospitalization and death (3) . A meta-analysis of confirmed COVID-19 cases from China placed Arch Med Res E20_644 4 hypertension, diabetes, cardiovascular disease and respiratory system disease as the most prevalent underlying NCDs, in that order (4) . Among hospitalized patients in Wuhan, China 64% had at least one comorbidity, with hypertension the most common, while 72.2% of patients with any NCD required intensive healthcare as against 37.3% among those without NCDs (5) . A meta-analysis or publications across various countries established that chronic kidney disease trebles the risk of severe COVID-19 infection (6) . The increased risk of NCD on COVID-19 severity has also been shown for the United States (7, 8) . Hospitalized patients in New York were reported with high NCD prevalence rates, with up to 56.6% reporting hypertension, 33.8% diabetes and 41.7% obesity (9) . The Mexican population has a high prevalence of chronic diseases and obesity, placing the population at a particular risk for severe COVID-19. For 2018 up to 18.4% of adults reported hypertension and 10.3% diabetes. With respect to risk factors, 36.1% of the adult population is obese, while 11.4% smokes (10,11). The identification of predictive factors for severe COVID-19 is useful to optimize hospital resources and to strengthen policies towards chronic disease prevention and control. The aim of this paper is to describe the prevalence of NCDs in patients with COVID-19 in the Mexican general population and to analyze the risks of hospitalization, use of ICU, intubation and death according to the report of underlying NCDs and modifiable risk factors. (12) . The MoH reports laboratory confirmed cases through two information channels: the epidemiological surveillance system for viral respiratory diseases (SISVER) and the National System for Epidemiological Surveillance (SINAVE). SISVER includes a sample of 475 health care units from a wide range of public and private providers in primary and hospital care in all states of the country who report 10% of ambulatory cases and 100% of hospitalized serious cases and deaths with suspected viral respiratory disease. Information is captured by physicians based on epidemiological study formats and includes patient information, suspected diagnosis and comorbidities (complement as necessary). (13, 14) . SINAVE includes all public and private health care units covering all diseases of obligatory reporting (15) . Of the total number of COVID-19 cases analyzed, the average age was 45.7 years, and 54.71% of cases were men. More than a half of cases (52.92%) were reported by MoH providers catering for the non-insured, followed closely by providers from the Mexican Institute of Social Security (IMSS) catering for formal private sector employees (Table 1) . Comorbidities were reported present in 47.40% of cases ( Table 2 ). The most prevalent NCD reported is hypertension (20.12%) and diabetes (16.44%) ( Patients with COVID-19 and NCD comorbidities had greater risk of hospitalization comparted to patients without an NCD diagnosis or risk factors, as shown by the odds ratio (OR) expressing the risk multiplier with respect to not having the NCD diagnosis or risk factor (Table 3) . CKD is the NCD that poses greatest hospitalization risk (OR 2.54), followed by immunosuppression (OR 2.17), diabetes (OR 1.98) and COPD (OR 1.34). Patients with modifiable risk factors also had a greater risk of hospitalization, of 1.29 in the case of obesity. Interestingly, asthma and smoking were found to be a protective factor of hospitalization (OR 0.83 and OR 0.93, respectively). Admission to the ICU also showed increased risks for patients with NCD and modifiable risk factors. Among patients with any NCD the risk was similar to hospitalization (OR1.89). The highest risk was observed in the case of diabetes (OR 1.66) followed by immunosuppression (OR 1.62). With regard to modifiable risk factors, cases with obesity had greater risk (OR 1.59). Again, smoking turned out to be a protective factor (OR 0.85). Similarly, the report of endotracheal intubation was associated to greater risk for patients with any NCD (OR1.95). The NCD posing greatest risk was diabetes (OR 1.68) followed by Arch Med Res E20_644 8 immunosuppression (OR 1.32). Asthma was found to be a protective factor of endotracheal intubation (OR 0.73). The modifiable risk factor of obesity increased the risk of intubation by 1.62 times, but no significant association was found with smoking. Regarding mortality, higher risk was reported for patients with NCDs and modifiable risk factors (OR 1.99). The highest risk was observed in the case of CKD (OR 2.31) followed by diabetes (OR 1.69). With regard to modifiable risk factors, cases with obesity had greater risk (OR 1.42). Again, asthma was found to be a protective factor of death (OR 0.82). Our study suggests that people with COVID-19 disease and presence of NCD comorbidities in Mexico had a higher likelihood to be hospitalized, to be admitted to the ICU and to be intubated. The NCD that places persons infected with COVID-19 at risk of being hospitalized is CKD, and for UCI admissión and endotraqueal intubation is diabetes. Limitations of our study are those of the sources of information based as it was on official reports stemming from a COVID-19 surveillance system that has not been adequately validated (12) . No analyses have been undertaken yet of the quality of the database, although anecdotal evidence suggests that quality has been improving on a daily basis. As in other countries, the number of confirmed COVID-19 cases is underreported, although this could be a greater concern in Mexico given low levels of testing (22) . Furthermore, the sentinel system reports cases based on a sample which may be biased towards MoH providers. These limitations pose minor challenges for our study as we aim to assess the relative risks posed by NCDs and modifiable risk factors on health services utilization; the completeness of reports would play a negligible error. However, health care Arch Med Res E20_644 9 institutions could be subjected to different internal constraints on health service utilization. Sampling biases would, could, therefore be more challenging. However, the observed distribution of cases across institutions does not deviate significantly over normal distribution of hospital utilization in Mexico across public institutions. Private providers, however, could be under-represented. NCD comorbidities represent a higher risk of hospitalization, and once interned, contribute less but still significantly to ICU admission and endotracheal intubation. For instance, a systematic review and meta-analyse reported that among 1382 COVID-19 patients, diabetes was the second more frequent comorbidity, and diabetic patients had a significant increased risk of ICU admission (OR 2.79, p <0.0001), and they also resulted to be at higher mortality risk (OR 3.21, p <0.0001) (16) . In showing that among patients with diabetes, severe cases were significantly more common than in non-severe patients (p <0.001) (17). Our results are congruent with previous studies, showing that a higher prevalence of NCD comorbidities and risk factors among COVID-19 patients as well as greater risk for hospitalization (3, 4, 6, 8, 9, 14, 15, 23) . Hypertension and diabetes are the most prevalent NCDs in patients with COVID-19 in Mexico, and with CKD, pose the most significant risk of hospitalization. Among the reported modifiable risk factors, obesity also places a significant challenge on hospitalization. While diabetes and hypertension prevalence are higher among COVID-19 patients than in the general population, obesity is somewhat lower (11). Asthma patients presented a protective factor for hospitalization, intubation and death in this Mexican population. Other countries have reported that is unclear if asthma increases the risk of contracting COVID-19, or increases the risk of worse outcomes from COVID-19 disease. Probably COVID-19 can trigger asthma exacerbations, given that viral respiratory infections are a frequent cause of asthma Arch Med Res E20_644 10 attacks (21) , and exacerbations that require emergency department visits and hospitalizations increase annually when viral infections increase (22) . However, studies from China and Korea did not find that patients with asthma had more risk to be hospitalized in the COVID-19 infection (18, 23, 24) . The low prevalence of Asthma as a chronic respiratory disease related to Covid-19, has conditioned asthma to be considered as a protective factor for covid-19 infection. This can be explained by immune response conditioned by chronic respiratory disease itself, as well as a different and routine treatment of asthmatic patients with inhaled corticosteroids alone or in combination with bronchodilators, which have demonstrated their ability to suppress viral replication and decrease the production of cytosines responsible for the inflammatory storm by COVID-19. A widely used drug among patients with asthma is montelukast, which have bronchodilator and anti-inflammatory effects, it even decreases the need for high doses of steroids (25) . Moreover, montelukast has exhibited antiviral efficacy against ZIKA infection in vitro and in vivo, showing that montelukast could disrupt the integrity of the virions to release the viral genomic RNA, hence irreversibly inhibiting viral infectivity (26) . Regarding the protective effect of smoking, another cross-sectional study in France showed that current smokers are less likely to develop severe COVID-19 disease. They hypothesized a protective mechanism for nicotine, which binds to ACE2 receptors, preventing the SARS-CoV-2 virus from attaching, reducing the amount of virus that enters lung cells (27) . Like our study, several biases could be incurred due to the fact that the way in which the physician compiled the information classified the patient as a "smoker" is unknown. There is no information on the quantity, frequency, or time of evolution. Likewise, when questioned, and according to the severity of the clinic condition, patients can deny smoking to a health professional. Another type of research design is necessary to test this hypothesis. Our study shows higher NCD comorbidity prevalence in confirmed COVID-19 cases than China but lower than the USA and European countries, except for diabetes. China reported hypertension present in 16.37-21.1% of studies, diabetes in 7.87-9.7% and smoking in 7.63% (4, 5, 28) . Among hospitalized patients in New York, hypertension was reported at 56.6%, obesity at 41.7, and diabetes at 33.8% (9) . Italy reports 17% of admissions diabetes, 49% hypertension, and 21% cardiovascular disease; in Sweden: 23% diabetes, 34% hypertension, and 16% chronic lung disease; while in Spain: 17% presented diabetes and 30% had cardiovascular disease (29) . with the increased release of inflammatory cytokines and cardiac enzymes such as troponin, which can cause diffuse microangiopathy with thrombosis. Inflammation in the heart can lead to myocarditis, failure, arrhythmias, acute coronary syndrome, and death (32, 33) . Human coronaviruses SARS-CoV and SARS-CoV-2 bind to their target cells through angiotensin-converting enzyme 2 (ACE2), which is expressed by epithelial cells of the lung, intestine, kidney, and blood vessels (34, 35) . The expression of ACE2 is significantly increased in patients with hypertension and diabetes types 1 and 2 treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Therefore, the increased expression of ACE2 facilitates infection with COVID-19, increasing the risk of developing severe and fatal COVID-19 (19) . Modifiable risk factors such as obesity and smoking have been proven its importance for COVID-19 severity. Obesity is association with a functional immune deficit, with disruption of pancreatic beta cells, and with the enhancement of thrombosis (20) , while smoking doubles the likelihood of severe COVID-19 infection (36) . However, information on these pathophysiological mechanisms is emerging and clinical trials are required to confirm this dynamic in the Mexican population. The COVID-19 pandemic has brought to the forefront once again the importance of NCD prevalence and control as cofactors of morbidity and mortality in conjunction with infectious diseases. Mexico has among the highest rates of CKD and diabetes in the world, yet persons living with diabetes are usually diagnose late, and most remain outside the boundaries of effective coverage of best practices and hence most suffer uncontrolled diabetes exposing them to complications (11). The COVID-19 epidemic should be further researched in the context of other NCD epidemics and underlying social and economic determinants and risk factors following a syndemic approach to enable predictions based on how interactions between epidemics amplify disease burden as well as improving disease prevention and care (37) . NCD and infectious disease control should be integrated Arch Med Res E20_644 13 with policies towards healthy spaces and environments, reducing disparities and tackling the social determinants of health, including education (38) . Cardiovascular problems, diabetes and obesity start from an early age, so primary prevention is necessary, through physical activity and screening programs from school age (39) . Regarding secondary prevention, it is necessary to strengthen patientphysician communication at the first and second levels of care to improve adherence to pharmacological and non-pharmacological treatment (40) . To tackle COVID-19 it is now more necessary than ever to determine predictive factors for severe infection to enable risk stratification, optimize reallocation of hospital resource, and guide public health recommendations and interventions (6) . The COVID-19 pandemic places Mexico at a particular risk now and in the future due to the high levels of co-morbidities accompanying infections and hospitalization as well as admittance to ICU and endotracheal intubation. Hypertension followed by diabetes are the most prevalent NCDs accompanying COVID-19 cases, while CKD poses a sever risk of hospitalization. Health policy in the post COVID-19 Mexico must place chronic diseases at the center of discussion to ensure health system integration with economic, social and environmental policies. The COVID-19 pandemic has brought to the fore the importance of addressing an epidemiological scenario where both infectious and chronic degenerative diseases coexist. Even with a COVID-19 vaccine available, the disease will remain, probably with a higher incidence than what is observed for seasonal influenza. It is therefore critical to redouble efforts to prevent and control NCDs in Mexico to reduce morbidity and mortality as well as health service utilization in a pandemic scenario of The authors declare no conflict of interest in this article. World Health Organization. Novel coronavirus -Disease outbreak 2020 World Health Organization World Health Organization. COVID-19 and NCDs 2020 Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Datos Abiertos de México -Información referente a casos COVID-19 en México -Bases de datos COVID-19 2020 Lineamiento estandarizado para la vigilancia epidemiológica y por laboratorio de la enfermedad respiratoria viral 2020 Datos Abiertos de México -Información referente a casos COVID-19 en México -Bases de datos COVID-19 2020 Norma Oficial Mexicana NOM-017-SSA2-1994, Para la vigilancia epidemiológica Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome Risk factors for severe COVID-19: Evidence from 167 hospitalized patients in Anhui Clinical Characteristics of Coronavirus Disease 2019 in China Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms The role of viruses in acute exacerbations of asthma Clinical characteristics of 140 patients infected with SARS-CoV Korean Society for Antimicrobial Therapy, Korean Society for Healthcareassociated Infection Control and Prevention The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis COVID-19) in the EU/EEA and the UK -eighth update 2020 Mexico | Institute for Health Metrics and Evaluation Noncommunicable diseases in the Region of the Americas: facts and figures The impact of 2019 novel coronavirus on heart injury: A systemic review and Meta-analysis The Science Underlying COVID-19: Implications for the Cardiovascular System Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases Smoking is Associated with COVID-19 Progression: A Meta Co-occurring epidemics, syndemics, and population health A Framework for Increasing Equity Impact in Obesity Prevention Preventive health services and physical activity improve health-related quality of life in Mexican older adults x-x Running Title: Risk of hospitalization and death in COVID-19 and chronic diseases.